NCT06066255 2024-02-20
CASPER
Institut Paoli-Calmettes
Phase 2 Unknown
Clinical Trials
189 trialsNCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT03193281 2023-11-29
KISS
University of Auckland, New Zealand
Phase 2 Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT04754035 2023-10-03
IMPROVE
IRCCS San Raffaele
Phase 2 Unknown
NCT04856215 2023-10-03
RITII
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 2 Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT03249870 2023-09-06
EWALL-INO
Versailles Hospital
Phase 2 Unknown
NCT05951855 2023-07-19
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01374841 2023-06-28
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
European Institute of Oncology
Phase 2 Unknown
NCT05576532 2023-06-28
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT05821738 2023-05-09
Avapritinib in CBF-AML With KIT Mutations
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05252403 2023-05-06
Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Phase 2 Unknown
NCT05823714 2023-04-21
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05809167 2023-04-12
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03883087 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT03883100 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT01593488 2023-03-24
CILI
National Cancer Institute, Naples
Phase 2 Unknown
NCT04749355 2023-03-09
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
BioSight Ltd.
Phase 2 Unknown
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT04809181 2023-02-21
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT02047578 2023-02-06
Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.
Seoul National University Hospital
Phase 2 Unknown
NCT05376852 2022-12-08
Case-Only
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05638763 2022-12-06
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT04913922 2022-11-08
AARON
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03460522 2022-11-02
Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL
Goethe University
Phase 2 Unknown
NCT05598593 2022-10-28
Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05413356 2022-10-19
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03624270 2022-10-04
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT04689815 2022-10-04
Oral Arsenic Trioxide for NPM1-mutated AML
The University of Hong Kong
Phase 2 Unknown
NCT03280160 2022-09-16
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
PETHEMA Foundation
Phase 2 Unknown
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05330364 2022-04-29
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Zhongda Hospital
Phase 2 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04867928 2022-03-16
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT03610438 2022-01-04
ALL2418
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT02071901 2021-12-01
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT04752527 2021-11-15
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05084027 2021-10-27
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03146468 2021-09-23
NIVALLO
Melbourne Health
Phase 2 Unknown
NCT00558519 2021-08-18
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT04992377 2021-08-05
BDHRT001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown